Fenofibrate Nanocrystallized
Brand name: Fenofibrate
Rank #396 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$23.2M
Total Cost
602,181
Total Claims
$23.2M
Total Cost
23,488
Prescribers
$38
Cost per Claim
50,688
Beneficiaries
1,284,738
30-Day Fills
$987
Avg Cost/Provider
26
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$23.2M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $23.2M total
Top Prescribers of Fenofibrate Nanocrystallized
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Henry Yee | Cardiology | Alhambra, CA | 656 | $27K |
| 2 | Roberto Gonzalez | Family Practice | Rio Grande City, TX | 282 | $20K |
| 3 | Teresa Alfonso | Internal Medicine | Miami, FL | 327 | $19K |
| 4 | Agustin Martinez | General Practice | Hialeah, FL | 418 | $18K |
| 5 | Dennis Pangtay | Family Practice | Irving, TX | 364 | $17K |
| 6 | Vy Nguyen | General Practice | Westminster, CA | 238 | $15K |
| 7 | Elizabeth Crabtree | Nurse Practitioner | Concord, NC | 1,005 | $15K |
| 8 | Jose Pena | Internal Medicine | Chula Vista, CA | 213 | $13K |
| 9 | Zachary Dickson | Nurse Practitioner | Chipley, FL | 238 | $13K |
| 10 | Glennette Haney | Nurse Practitioner | Alton, MO | 393 | $13K |
| 11 | Dhun Sethna | Cardiology | Christiansburg, VA | 248 | $12K |
| 12 | Hector Colombany Lorenzo | Cardiology | Aguadilla, PR | 761 | $12K |
| 13 | Razmik Ohanjanian | Internal Medicine | Glendale, CA | 457 | $12K |
| 14 | Sohail Davoudian | Internal Medicine | Redondo Beach, CA | 210 | $12K |
| 15 | Elsa Valero | Family Practice | Berwyn, IL | 159 | $12K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 393 | Lactulose (Lactulose) | $23.6M | 538,677 |
| 394 | Siponimod (Mayzent) | $23.5M | 2,195 |
| 395 | Droxidopa (Droxidopa) | $23.4M | 9,058 |
| 396 | Fenofibrate Nanocrystallized (Fenofibrate) | $23.2M | 602,181 |
| 397 | Ravulizumab-Cwvz (Ultomiris) | $23.1M | 428 |
| 398 | Roflumilast (Roflumilast) | $22.8M | 97,022 |
| 399 | Romosozumab-Aqqg (Evenity (2 Syringes)) | $22.3M | 9,087 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology